Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The tumor bulk is composed of a highly heterogeneous population of cancer cells, as well as a large variety of resident and infiltrating host cells, extracellular matrix proteins, and secreted proteins, collectively known as the tumor microenvironment (TME). The TME is essential for driving tumor development by promoting cancer cell survival, migration, metastasis, chemoresistance, and the ability to evade the immune system responses. Therapeutically targeting tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), regulatory T-cells (T-regs), and mesenchymal stromal/stem cells (MSCs) is likely to have an impact in cancer treatment. In this review, we focus on describing the normal physiological functions of each of these cell types and their behavior in the cancer setting. Relying on the specific surface markers and secreted molecules in this context, we review the potential targeting of these cells inducing their depletion, reprogramming, or differentiation, or inhibiting their pro-tumor functions or recruitment. Different approaches were developed for this targeting, namely, immunotherapies, vaccines, small interfering RNA, or small molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“After the initial state of the tumor, the TME (in particular, the immune TME) is modified to support and promote the tumor development while suppressing immune cell-mediated cytotoxicity [2].”
Remodelling the extracellular matrix in development and disease
Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367 · cited 4×
“Communication between CAFs and cancer cells also involve extracellular microvesicles that transmit biological information by carrying microRNAs, long non-coding RNAs (lncRNAs), proteins, or metabolites, both locally and at distance, thereby involved in preparing distant pre-metastatic niches (reviewed in Reference [23…”
BackgroundInfluentialThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
The extracellular matrix at a glance
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.023820 · Cited by 4,334 · cited 1×
“The ECM is mainly composed of collagens (type I, III, and V), elastin, fibrin, fibronectins, proteoglycans, and glycosaminoglycans, creating a three-dimensional network sheltering other stromal cells (immune, vascular, and glial cells, and neurons) [200].”
BackgroundMicroenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · cited 1×
“PPARγ agonists, which are suppressive for the Gpr132 axis, or siRNA silencing of Gpr132, was successfully used to desensitize TAMs to lactate stimulation in a breast tumor model [80,81].”
MethodCCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“These TAMs can be derived from resident macrophages [19] or attracted from bone marrow and spleen to the tumor site thanks to the CCL2 (MCP-1) and CCL5 (RANTES) chemokines produced by the tumors, fibroblasts, endothelial cells, and even by the TAMs themselves [20].”
BackgroundÖzdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681 · cited 1×
“Strategies attempting to ablate CAFs from tumors using cell subset markers provided promising therapeutic benefits when targeting the FAPα+ fibroblasts in pancreatic carcinoma [241], but not the αSMA+ subsets [242], further strengthening the functional diversity of these distinct CAF populations.”
BackgroundDistinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 2×
“Colony-stimulating factor-1 (CSF-1) is also a monocyte/macrophage attractant, as well as a macrophage survival and polarization signal, which is highly important in tumors [21].”
BackgroundElyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · cited 1×
“identified, by fluorescent analysis cell-sorting, four distinct CAF subsets in human breast cancer that accumulate differentially in tumors and juxta-tumors, one of these being functionally endowed with immunosupressive properties [213].”
BackgroundEssential role of Stat6 in IL-4 signalling
Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S.-I., Nakanishi, K., Yoshida, N., Kishimoto, T., & Akira, S. (1996) · Nature · doi:10.1038/380627a0 · Cited by 1,557 · cited 1×
“M2 polarization is induced by the release of IL-4, IL-13, or IL-10 by damaged cells, resulting in activation of the STAT6 transcription factor through the JAK–STAT pathway [14].”
BackgroundMacrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · cited 1×
“Through their pro-tumor functions, TAMs are also able to promote the recovery of tumors in mouse models following chemotherapies, radiotherapies, or immunotherapies [30].”
BackgroundSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · cited 1×
“Using an experimental model of Fc-receptor deficient mice, the anti-tumor effect of the anti-CTLA4 antibody was shown to be dependent on antibody-dependent cellular cytotoxicity of TI T-regs instead of re-activating conventional T-cells [135].”
MethodRole of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404 · cited 1×
“The cellular composition of the TME is highly variable and could include almost all immune cell types such as CD8, CD4, and γδ T-lymphocytes, macrophages, natural killer (NK) cells, dendritic cells (DC), B-cells, and mast cells, as well as fibroblasts, neuroendocrine cells, adipose cells, endothelial cells, and mesenc…”
BackgroundRies, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · cited 7×
“Moreover patients treated by PD-1 therapy exhibited CD8 T-cells expressing CD28 [138].”
BackgroundInfluentialOkabe, Y., & Medzhitov, R. (2014) · Cell · doi:10.1016/j.cell.2014.04.016 · Cited by 884
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871 · cited 1×
“T-regs regulate immune responses through four major mechanisms [118]: (i) secretion of inhibitory cytokines such as IL-10, IL-35, and TGF-β; (ii) direct cytolysis of target cells by the secretion granzyme-A, granzyme-B, and perforin [119]; (iii) IL-2 deprivation due to a high-affinity for CD25 (IL-2 receptor) [120]; a…”
BackgroundBartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M., Madsen, C. D., Lindgren, D., Pekar, G., Karlsson, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07582-3 · Cited by 826
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Qian, B., Deng, Y., Im, J. H., Muschel, R. J., Zou, Y., Li, J., Lang, R. A., & Pollard, J. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006562 · Cited by 664 · cited 1×
“In a murine xenograft model for cutaneous T-cell lymphoma, the reduction of tumor growth was associated with a decrease in pSTAT3 and macrophage number [43]; the same association was observed in other preclinical mouse models of bone metastasis from lung cancer [44], lung metastasis from breast cancer [45], or melanom…”
BackgroundInterferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627
Georgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609 · cited 2×
“This was shown as being dependent on the inhibitory Fc-receptor, FcγRIIB [51].”
BackgroundCatenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561 · cited 1×
“Further supporting the tumor restraining effect of the Hedgehog pathway, a clinical trial that combined chemotherapy with IPI-926, a small-molecule inhibitor of the Hedgehog pathway, was aborted due to a shortened patient overall survival (NCT01130142) [240].”
BackgroundClass IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558 · cited 1×
“Several synthetic molecules can also actively reverse the M2 phenotype of TAMs such as TMP195, an HDAC inhibitor, in breast cancer mouse models, or paclitaxel, an anti-microtubule agent, in patients with ovarian carcinoma [73,74].”
BackgroundControl of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Takenaka, M. C., Gabriely, G., Rothhammer, V., Mascanfroni, I. D., Wheeler, M. A., Chao, C.-C., Gutiérrez-Vázquez, C., Kenison, J., Tjon, E. C., Barroso, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0370-y · Cited by 517 · cited 2×
“These cells express at their surface the scavenger receptor, CD163, and the mannose receptor, CD206, and also have immunosuppressive functions neutralizing recruitment and functions of cytotoxic CD8 T-cells and natural killer cells through the secretion of IL-10 and TGF-β in the TME [26,27].”
BackgroundMembrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression
Goossens, P., Rodriguez-Vita, J., Etzerodt, A., Masse, M., Rastoin, O., Gouirand, V., Ulas, T., Papantonopoulou, O., Van Eck, M., Auphan-Anezin, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.016 · Cited by 502
Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo
Zhu, W., Huang, L., Li, Y., Zhang, X., Gu, J., Yan, Y., Xu, X., Wang, M., Qian, H., & Xu, W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.10.002 · Cited by 488 · cited 1×
“They also were described to enhance vascular endothelial growth factor (VEGF) expression in tumor cells by activating the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway [171].”
BackgroundWanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420 · cited 1×
“Several synthetic molecules can also actively reverse the M2 phenotype of TAMs such as TMP195, an HDAC inhibitor, in breast cancer mouse models, or paclitaxel, an anti-microtubule agent, in patients with ovarian carcinoma [73,74].”
BackgroundDe Wever, O., Nguyen, Q., Van Hoorde, L., Bracke, M., Bruyneel, E., Gespach, C., & Mareel, M. (2004) · The FASEB Journal · doi:10.1096/fj.03-1110fje · Cited by 402
Ontogeny of Tissue-Resident Macrophages
Hoeffel, G., & Ginhoux, F. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00486 · Cited by 364
Interactions between mesenchymal stem cells and the immune system
Li, N., & Hua, J. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2473-5 · Cited by 338
A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
Auciello, F. R., Bulusu, V., Oon, C., Tait-Mulder, J., Berry, M., Bhattacharyya, S., Tumanov, S., Allen-Petersen, B. L., Link, J., Kendsersky, N. D., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1212 · Cited by 332
Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis
Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005) · Cell · doi:10.1016/j.cell.2005.09.030 · Cited by 324
Qiao, L., Xu, Z.-L., Zhao, T.-J., Ye, L.-H., & Zhang, X.-D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.032 · Cited by 313 · cited 1×
“Although MSCs can halt cancer progression by inducing apoptosis, suppressing signaling pathways, initiating cell-cycle arrest, and increasing infiltration of monocytes and granulocytes [165,166], the majority of publications report pro-tumor activities.”
BackgroundA stromal address code defined by fibroblasts
Parsonage, G., Filer, A. D., Haworth, O., Nash, G. B., Rainger, G. E., Salmon, M., & Buckley, C. D. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.11.014 · Cited by 297
Weizman, N., Krelin, Y., Shabtay-Orbach, A., Amit, M., Binenbaum, Y., Wong, R. J., & Gil, Z. (2014) · Oncogene · doi:10.1038/onc.2013.357 · Cited by 281
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268 · cited 1×
“TAMs also represent a strong source of iron, which is essential to tumor development [28].”
BackgroundBaer, C., Squadrito, M. L., Laoui, D., Thompson, D., Hansen, S. K., Kiialainen, A., Hoves, S., Ries, C. H., Ooi, C.-H., & De Palma, M. (2016) · Nature Cell Biology · doi:10.1038/ncb3371 · Cited by 259 · cited 1×
“For instance, targeting of miRNA-processing enzyme DICER in macrophages with lysozyme-M-driven Cre prompts M1-like TAM reprogramming in lung carcinoma and MC38 tumors [67].”
BackgroundRegulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
Le, D. T., & Jaffee, E. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3912 · Cited by 240
Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation
Procopio, M.-G., Laszlo, C., Al Labban, D., Kim, D. E., Bordignon, P., Jo, S.-H., Goruppi, S., Menietti, E., Ostano, P., Ala, U., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3228 · Cited by 223 · cited 1×
“Aging and fibroblast senescence are also known to participate in tissue-resident fibroblast activation [205], and may play a role in malignancy.”
BackgroundZhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., Cullinan, D. R., Luo, J., Bearden, A. R., Lavine, K. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.018 · Cited by 180
The Multifaceted Role of Heme in Cancer
Fiorito, V., Chiabrando, D., Petrillo, S., Bertino, F., & Tolosano, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01540 · Cited by 129
Catecholamines contribute to the neovascularization of lung cancer via tumor-associated macrophages
Xia, Y., Wei, Y., Li, Z.-Y., Cai, X.-Y., Zhang, L.-L., Dong, X.-R., Zhang, S., Zhang, R.-G., Meng, R., Zhu, F., et al. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.06.004 · Cited by 103
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01719-5 · Cited by 693
Rapp, M., Wintergerst, M. W. M., Kunz, W. G., Vetter, V. K., Knott, M. M. L., Lisowski, D., Haubner, S., Moder, S., Thaler, R., Eiber, S., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20170277 · Cited by 271
Zi, Y., Yang, K., He, J., Wu, Z., Liu, J., & Zhang, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114449 · Cited by 268
The Multifaceted Role of Heme in Cancer
Fiorito, V., Chiabrando, D., Petrillo, S., Bertino, F., & Tolosano, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01540 · Cited by 129
Metadata
- Authors
- Laplagne, C., Domagala, M., Le Naour, A., Quemerais, C., Hamel, D., Fournié, J.-J., Couderc, B., Bousquet, C., Ferrand, A., & Poupot, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-09-23
- Volume
- 20
- Issue
- 19
- Pages
- 4719
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2974912304
- Cited by
- 72
- References
- 52
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.